These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 7500097)

  • 1. Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A.
    Sheean GL; Lees AJ
    J Neurol Neurosurg Psychiatry; 1995 Dec; 59(6):601-7. PubMed ID: 7500097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A.
    Houser MK; Sheean GL; Lees AJ
    J Neurol Neurosurg Psychiatry; 1998 May; 64(5):577-80. PubMed ID: 9598669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muscle paralysis produced by botulinum toxin type A injection in treated torticollis patients compared with toxin naive individuals.
    Sloop RR; Cole D; Patel MC
    Mov Disord; 2001 Jan; 16(1):100-5. PubMed ID: 11215566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
    Truong DD; Cullis PA; O'Brien CF; Koller M; Villegas TP; Wallace JD
    Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of spasmodic torticollis with local injections of botulinum toxin. One-year follow-up in 37 patients.
    Poewe W; Schelosky L; Kleedorfer B; Heinen F; Wagner M; Deuschl G
    J Neurol; 1992 Jan; 239(1):21-5. PubMed ID: 1541964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of resistance to botulinum toxin type A in patients with torticollis.
    Greene P; Fahn S; Diamond B
    Mov Disord; 1994 Mar; 9(2):213-7. PubMed ID: 8196686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin for the treatment of cervical dystonia.
    Tintner R; Jankovic J
    Expert Opin Pharmacother; 2001 Dec; 2(12):1985-94. PubMed ID: 11825330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A.
    Greene PE; Fahn S
    Mov Disord; 1993 Oct; 8(4):479-83. PubMed ID: 8232357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of selective ramisectomy for botulinum toxin resistant torticollis.
    Ford B; Louis ED; Greene P; Fahn S
    J Neurol Neurosurg Psychiatry; 1998 Oct; 65(4):472-8. PubMed ID: 9771768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-related botulinum toxin effects on muscle fiber conduction velocity in non-injected muscles.
    Lange F; van Weerden TW; van der Hoeven JH
    Clin Neurophysiol; 2007 Nov; 118(11):2398-403. PubMed ID: 17897878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Electromyography monitoring in the treatment of torticollis with botulinum toxin].
    Domzał TM; Tutaj A
    Pol Merkur Lekarski; 2000 Jul; 8(49):474-5. PubMed ID: 11070717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The clinical usefulness of botulinum toxin type A for spasmodic torticollis and facial spasm].
    Mezaki T; Kaji R; Kimura J; Osame M; Mizuno Y; Hirayama K; Maruyama S; Iwata M; Kanazawa I; Kinoshita M
    No To Shinkei; 1995 Aug; 47(8):749-54. PubMed ID: 7546919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An electrophysiological approach to the diagnosis of neurogenic dysphagia: implications for botulinum toxin treatment.
    Alfonsi E; Merlo IM; Ponzio M; Montomoli C; Tassorelli C; Biancardi C; Lozza A; Martignoni E
    J Neurol Neurosurg Psychiatry; 2010 Jan; 81(1):54-60. PubMed ID: 19762326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Botulinum toxin type B in the management of dystonia non-responsive to botulinum toxin type A].
    Cardoso F
    Arq Neuropsiquiatr; 2003 Sep; 61(3A):607-10. PubMed ID: 14513166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of cervical dystonia with botulinum toxin.
    Jankovic J
    Mov Disord; 2004 Mar; 19 Suppl 8():S109-15. PubMed ID: 15027062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to botulinum toxin F in seronegative botulinum toxin A--resistant patients.
    Greene PE; Fahn S
    Mov Disord; 1996 Mar; 11(2):181-4. PubMed ID: 8684389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy.
    Dressler D
    Mov Disord; 2004 Mar; 19 Suppl 8():S92-S100. PubMed ID: 15027060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia.
    Jankovic J; Hunter C; Dolimbek BZ; Dolimbek GS; Adler CH; Brashear A; Comella CL; Gordon M; Riley DE; Sethi K; Singer C; Stacy M; Tarsy D; Atassi MZ
    Neurology; 2006 Dec; 67(12):2233-5. PubMed ID: 17190952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ptosis as a remote effect of therapeutic botulinum toxin B injection.
    Racette BA; Lopate G; Good L; Sagitto S; Perlmutter JS
    Neurology; 2002 Nov; 59(9):1445-7. PubMed ID: 12427903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia.
    Berman B; Seeberger L; Kumar R
    Mov Disord; 2005 Feb; 20(2):233-7. PubMed ID: 15455449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.